UNSPSC 51351510: Megestrol

This classification denotes a therapeutic progestin with the molecular formula C22H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EA6LD1M70M, chemically known as 17-hydroxy-6-methylpregna-4,6-diene-3,20-dione but generally known as megestrol, which bears US NIH Compound Identifier 19090. European Medicines Agency schedules Megestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08712MIG. World Health Organization schedules megestrol in its Anatomical Therapeutic Chemical (ATC) Classification.

UNSPSC 51351510 Megestrol is a Commodity code covering the procurement of this synthetic progestin medication by state and local health agencies. State and local governments purchase megestrol primarily through health departments, correctional facilities, state hospitals, and Medicaid programs to treat conditions including appetite loss, cachexia, and certain cancers in inpatient and outpatient settings. The code encompasses megestrol acetate in multiple formulations—tablets, oral suspensions, and injectable preparations—and spans both brand-name and generic sourcing. Issuing bodies include state health and human services departments, county health systems, municipal hospitals, state corrections departments, and special-purpose health districts that operate clinics and emergency services.

The source provides no recent state and local contract opportunities for megestrol, so current procurement activity under this code cannot be characterized by geography, issuing-body concentration, or representative solicitation examples. This may reflect either low activity in posted notices, limited frequency of standalone megestrol purchases (which are often bundled into broader pharmaceutical or medical-supply contracts under higher-tier codes), or procurement cycles that do not align with publicly available opportunity records. Business development professionals evaluating this code should review whether megestrol appears in broader pharmaceutical, generic drug, or health-system supply agreements rather than as a standalone commodity line.